-+ 0.00%
-+ 0.00%
-+ 0.00%

Biohaven Presents Preclinical Data For BHV-1420 At American Society Of Nephrology Kidney Week 2026

Benzinga·10/26/2026 11:37:08
Listen to the news

Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado. BHV-1420 is a novel TRAP extracellular protein degrader designed to selectively eliminate the anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies that drive membranous nephropathy (MN).